Abstract
Despite advances in HIV treatment and the availability of 22 approved antiretroviral drugs, newer compounds are needed that are better tolerated, less toxic, more convenient, or have improved activity against drug-resistant viruses. In addition to newer agents in development in traditional antiretroviral classes (reverse transcriptase inhibitors, protease inhibitors), a number of compounds in newer mechanistic classes also are under development, including entry inhibitors, integrase inhibitors, and maturation inhibitors. This review focuses on some of the investigational antiretroviral compounds that have reached clinical development and that offer the most promise for treatment of HIV-infected individuals.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
